Benzimidazol-2-amines as MIDH1 inhibitors

US9951027B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hartmut Rehwinkel · Berlin, DE
• Holger Siebeneicher · Berlin, DE
• Sonja Anlauf · Wuppertal, DE
• Duy Nguyen · Berlin, DE
• Olaf Panknin · Berlin, DE
• Sven Ring · Jena, DE
• Wolfgang Schwede · Berlin, DE
• Marcus Bauser · Berlin, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Stefan Kaulfuss · Berlin, DE
• Roland Neuhaus · Berlin, DE

Key dates

• Filing date: Feb 10, 2015
• Grant date: Apr 24, 2018
• Expiry date: Feb 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.